PReS-FINAL-2130-A: Effectiveness of intravenous cyclophosphamide in severe or refractory juvenile dermatomyositis - a national cohort study UK and Ireland

Ítems similars

• PReS-FINAL-2130: Antibodies to MDA5 correlate with a distinct phenotype in children with juvenile dermatomyositis, including higher risk of lung involvement and ulcerative skin disease
  per: Moraitis, E, et al.
  Publicat: (2013)
• Comparison of data from the juvenile dermatomyositis national (UK & Ireland) cohort biomarker study and repository for idiopathic inflammatory myopathies with a survey of current practice throughout the UK and Ireland
  per: Beard L, et al.
  Publicat: (2011-09-01)
• Comparison of data from the juvenile dermatomyositis national (UK & Ireland) cohort biomarker study and repository for idiopathic inflammatory myopathies with a survey of current practice throughout the UK and Ireland
  per: Martin, N, et al.
  Publicat: (2011)
• Comparison of Children With Onset of Juvenile Dermatomyositis Symptoms Before or After Their Fifth Birthday in a UK and Ireland Juvenile Dermatomyositis Cohort Study
  per: Martin, N, et al.
  Publicat: (2012)
• PReS-FINAL-2172: Efficacy of corticosteroids and intravenous cyclophosphamide for patients with juvenile systemic sclerosis
  per: Kikuchi, M, et al.
  Publicat: (2013)